RADx Variant Task Force Program for Assessing the Impact of Variants on SARS-CoV-2 Molecular and Antigen Tests

Area of Science:

• Virology
• Genomics
• Infectious Diseases

Background:

• SARS-CoV-2 continuously evolves, with new lineages like Alpha and Delta rapidly emerging and altering strain prevalence.
• Understanding viral genetic diversity is essential for maintaining the efficacy of diagnostic tests, vaccines, and therapies for COVID-19.

Purpose of the Study:

• To outline the approach and activities of the National Institutes of Health's Rapid Acceleration of Diagnostics (RADx) Variant Task Force.
• To assess the impact of emerging SARS-CoV-2 variants on the performance of in vitro diagnostic tests.

Main Methods:

• Utilizing a combination of in silico modeling and in vitro testing to evaluate the effects of SARS-CoV-2 mutations.
• Collaborating with clinical laboratories, the Food and Drug Administration (FDA), and the Centers for Disease Control and Prevention (CDC).

Main Results:

• The RADx Variant Task Force employs a systematic approach to monitor SARS-CoV-2 genetic diversity.
• The task force's activities ensure diagnostic test performance against evolving viral lineages.

Conclusions:

• The RADx Variant Task Force plays a critical role in safeguarding the reliability of diagnostic testing in the face of SARS-CoV-2 evolution.
• Proactive monitoring and assessment of viral variants are crucial for public health preparedness and response to COVID-19.